“The world’s first life-saving gene therapy for children, developed by GlaxoSmithKline and Italian scientists, was approved for sale in Europe on Friday, in a step forward for the pioneering technology to fix faulty genes.
Called Strimvelis, it is designed for a tiny number of children with ADA Severe Combined Immune Deficiency (ADA-SCID). SCID is sometimes known as “bubble baby” disease, since those born with it have immune systems so weak they must live in germ-free environments.
Strimvelis is the second gene therapy to be approved in Europe, after UniQure’s Glybera, which treats a rare adult blood disorder.”
Share this entry
- The American Health Council Welcomes Hartmuth B. Bittner, MD, Ph.D., FACS to its Board of Physicians September 19, 2018
- Valeria Robinson-Baker, B.S.Pharm., R.Ph., C.Ph., is Appointed to the American Health Council’s Industry Board September 18, 2018
- The American Health Council Names Norman Tomaka, BS, Pharm.MS, FAPhA to its Industry Board September 10, 2018
- Samuel Ashu, Pharm.D., is Elected to the American Health Council’s Industry Board September 7, 2018
- Erin Engel, DPM is Appointed to the American Health Council’s Board of Physicians August 28, 2018
- Brittany Bento, PA-C is Appointed to the American Health Council’s Board of Physicians August 27, 2018